New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > BR Metastatic - vinORELBine [oral]

BR Metastatic - vinORELBine [oral]

Treatment Overview

Cycle 1 (and all further cycles) - 21 days

Cycle length:
21

If well tolerated, consider increasing the dose of vinorelbine to 80 mg/m2 ONCE a week from week 4.

Cycle details

Cycle 1 (and all further cycles) - 21 days

Medication Dose Route Days Max Duration
ondansetron 8 mg oral administration 1, 8, 15
vinORELBine * 60 mg/m² oral administration 1, 8, 15
ondansetron 8 mg oral administration 1, 8, 15
domperidone 10 mg Three times daily oral administration 1
docusate sodium + sennoside B 2 Tablet(s) oral administration 1

If well tolerated, consider increasing the dose of vinorelbine to 80 mg/m2 ONCE a week from week 4.

Full details

Cycle 1 (and all further cycles) - 21 days

Day: 1

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:
ONE hour prior to chemotherapy.
vinORELBine * 60 mg/m² oral administration
Instructions:
Take with food. Swallow whole, do not crush or chew. Round dose to closest multiple of 20 mg and/or 30 mg capsules.
ondansetron 8 mg oral administration
Instructions:
EIGHT hours after chemotherapy OR before bed.
domperidone 10 mg Three times daily oral administration
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.
docusate sodium + sennoside B 2 Tablet(s) oral administration
Instructions:
At night when required for constipation. Each tablet contains docusate sodium 50 mg + sennoside B 8 mg.

Day: 8

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:
ONE hour prior to chemotherapy.
vinORELBine * 60 mg/m² oral administration
Instructions:
Take with food. Swallow whole, do not crush or chew. Round dose to closest multiple of 20 mg and/or 30 mg capsules.
ondansetron 8 mg oral administration
Instructions:
EIGHT hours after chemotherapy OR before bed.

Day: 15

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:
ONE hour prior to chemotherapy.
vinORELBine * 60 mg/m² oral administration
Instructions:
Take with food. Swallow whole, do not crush or chew. Round dose to closest multiple of 20 mg and/or 30 mg capsules.
ondansetron 8 mg oral administration
Instructions:
EIGHT hours after chemotherapy OR before bed.

Supportive Care Factors

Factor Value
Constipation risk: laxatives are usually prescribed
Emetogenicity: Medium

References

1. Aapro, M. and J. Finek. 2012. "Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results." Cancer Treat Rev 38(2):120-126, PMID: 21742438

2. Jensen, L. H., K. Osterlind and C. Rytter. 2008. "Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC." Lung Cancer 62(1):85-91., PMID: 18372075

3. Freyer, G., T. Delozier, M. Lichinister, et al. 2003. "Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy." J Clin Oncol 21(1):35-40, PMID: 12506167

4. Amadori, D, P Koralewski, A Tekiela, et al. 2001. "Efficacy and safety of navelbine oral (NVBo) in first line metastatic breast cancer (MBC)." Eur J Cancer 37 (Suppl. 6) (abstract 713)

5. Blancas, I., S. Morales, N. Diaz, et al. 2010. "Efficacy and safety of oral vinorelbine (NVBO) in first-or second-line metastatic breast cancer (MBC)." J Clin Oncol; 28:15S (abstract 1090)

6. Mansour, M., and Haddad, N. 2010. "Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previously treated with adjuvant anthracyclines and/or taxanes." Proc 21st International Congress on Anti-Cancer Treatment." (abstract 627)

7. Addeo, R., V. Faiola, G. Cennamo, et al. 2009. "A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: A phase II trial." J Clin Oncol 27:15 Suppl 1 (p 1085)

8. Bartsch. R, U. Pluschnig, C. Wenzel, et al. 2008. "Oral Vinorelbine in Metastatic Breast Cancer - The Vienna Experience." Ann Oncol; 19 (Suppl. 8) (abstract 160)

9. Palomo, A. G., I. Glogowska, H. Sommer, et al. 2012. "Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy." Anticancer Res 32(10):4539-4545., PMID: 23060583

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.